Goldman Sachs downgraded HealthEquity (HQY) to Sell from Neutral with an $89 price target After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note. The firm thinks the stock’s multiple will come under pressure until the next leg of growth opportunity emerges.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- HealthEquity price target raised to $125 from $120 at KeyBanc
- HealthEquity initiated with an Overweight at Barclays
- HealthEquity Inc. Reports Strong Q3 Earnings and Growth
- HealthEquity price target raised to $120 from $117 at Deutsche Bank
- HealthEquity’s Strong Q3 Performance and Raised Guidance Justify Buy Rating with Significant Upside Potential